| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Intellia Therapeutics Inc (NASDAQ: NTLA)
NTLA Technical Analysis
5
| As on 9th Jun 2023 NTLA STOCK Price closed @ 43.24 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 66.27 & Strong Sell for SHORT-TERM with Stoploss of 96.55 we also expect STOCK to react on Following IMPORTANT LEVELS. |
NTLASTOCK Price
| Open | 44.61 | Change | Price | % |
| High | 44.61 | 1 Day | -0.12 | -0.28 |
| Low | 42.68 | 1 Week | 5.69 | 15.15 |
| Close | 43.24 | 1 Month | 7.01 | 19.35 |
| Volume | 812600 | 1 Year | -79.43 | -64.75 |
| 52 Week High 128.26 | 52 Week Low 33.21 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| NTLA Daily Charts |
NTLA Intraday Charts |
Whats New @ Bazaartrend |
NTLA Free Analysis |
|
|
NTLA Important Levels Intraday
| RESISTANCE | 46.96 |
| RESISTANCE | 45.77 |
| RESISTANCE | 45.03 |
| RESISTANCE | 44.29 |
| SUPPORT | 42.19 |
| SUPPORT | 41.45 |
| SUPPORT | 40.71 |
| SUPPORT | 39.52 |
NTLA Forecast April 2024
| 4th UP Forecast | 114.56 |
| 3rd UP Forecast | 91.69 |
| 2nd UP Forecast | 77.55 |
| 1st UP Forecast | 63.41 |
| 1st DOWN Forecast | 23.07 |
| 2nd DOWN Forecast | 8.93 |
| 3rd DOWN Forecast | -5.21 |
| 4th DOWN Forecast | -28.08 |
NTLA Weekly Forecast
| 4th UP Forecast | 74.86 |
| 3rd UP Forecast | 64.72 |
| 2nd UP Forecast | 58.45 |
| 1st UP Forecast | 52.18 |
| 1st DOWN Forecast | 34.30 |
| 2nd DOWN Forecast | 28.03 |
| 3rd DOWN Forecast | 21.76 |
| 4th DOWN Forecast | 11.62 |
NTLA Forecast2024
| 4th UP Forecast | 229.83 |
| 3rd UP Forecast | 169.99 |
| 2nd UP Forecast | 133 |
| 1st UP Forecast | 96.01 |
| 1st DOWN Forecast | -9.53 |
| 2nd DOWN Forecast | -46.52 |
| 3rd DOWN Forecast | -83.51 |
| 4th DOWN Forecast | -143.35 |
Intellia Therapeutics Inc ( NASDAQ USA Symbol : NTLA )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
NTLA Business Profile
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Address: 40 Erie Street, Cambridge, MA, United States, 02139
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service